GLP-1 Receptor Agonists and Persistent Gastroparesis Risk: What These Abstracts Do and Do Not Show

Why this question is hard to answer from these abstracts

The topic here is long-term adverse effects on gastric motility and whether GLP-1 receptor agonists might be linked to persistent gastroparesis. In the provided abstracts, that exact endpoint is not directly studied. None of the abstracts reports formal gastric emptying testing, a diagnosed gastroparesis cohort, symptom duration after stopping therapy, or a direct estimate of persistent gastroparesis risk. What they do report is broader gastrointestinal adverse events such as nausea, vomiting, diarrhea, and treatment discontinuation due to gastrointestinal symptoms in different study settings. That means these abstracts offer partial context on tolerability, not a direct answer to the long-term motility question.

Because the evidence types differ, interpretation also differs. Some abstracts summarize randomized human trials, some describe observational real-world cohorts, and one is a pharmacovigilance analysis of safety reports. In this explainer, each study is kept separate so that reported endpoints are not overstated. Sources 2, 5, and 6 are the most relevant to gastrointestinal adverse events, while source 1 provides indirect context on postmarketing reporting patterns without reporting gastric motility endpoints.

Sources: [2][5][6][1]

In a phase 2 obesity summary, survodutide was associated with common gastrointestinal adverse events

In source 2, the population was adults with body mass index at or above 27 kg/m2 without diabetes in a phase 2 trial of survodutide, an investigational dual glucagon and GLP-1 receptor agonist. The abstract reports body-weight reduction data and states that gastrointestinal adverse events, including nausea, vomiting, and diarrhea, were common. It also says these events were influenced by dose escalation.

For the gastric motility question, the key point is what was and was not measured in this abstract. In this experiment summary, the reported safety endpoints are general gastrointestinal adverse events and tolerability. The abstract does not mention gastric emptying, delayed gastric motility testing, gastroparesis diagnoses, persistence of symptoms after discontinuation, or long-term follow-up focused on stomach function. It therefore shows that gastrointestinal symptoms were common in this study context, but it does not quantify persistent gastroparesis risk.

Sources: [2]

In a phase 3 cardiovascular safety trial, orforglipron had frequent gastrointestinal adverse events and discontinuations

In source 5, researchers conducted a phase 3, event-driven, randomized, open-label, active-comparator trial in adults with type 2 diabetes and obesity or overweight who were at increased cardiovascular risk. Participants were assigned to oral orforglipron or injectable insulin glargine, and the primary endpoint was time to major adverse cardiovascular events over a median follow-up of 2 years.

For this article's topic, the relevant finding is that gastrointestinal adverse events were the most frequent adverse event with orforglipron and the most common reason for treatment discontinuation. This tells readers that, in this human trial, gastrointestinal tolerability was a prominent safety issue during treatment. However, the abstract does not identify the specific gastrointestinal event spectrum in detail beyond that summary, and it does not report gastric motility measurements, diagnosed gastroparesis, persistence after stopping the drug, or whether any stomach-related symptoms became chronic. So this abstract supports the idea that gastrointestinal adverse events matter operationally in long-term trials, but not that persistent gastroparesis risk has been established.

Sources: [5]

In a 24-week Japanese real-world study, tirzepatide was linked with gastrointestinal symptoms

In source 6, the study population was 88 Japanese people with type 2 diabetes in a multicenter, retrospective, single-arm observational study. The primary outcomes were changes in glycated hemoglobin and body mass index over 24 weeks after starting low-dose tirzepatide. The abstract also included patient-reported outcome analyses and a brief safety summary.

In this study, the major adverse events linked with tirzepatide were gastrointestinal symptoms. That finding adds real-world context that stomach- or bowel-related symptoms were notable enough to be highlighted in the abstract. But the abstract does not say which symptoms predominated, how long they lasted, whether they resolved, whether any participant developed diagnosed gastroparesis, or whether gastric motility was objectively assessed. Because it is a single-arm retrospective study, it also reports symptom occurrence without a comparator group in the abstract itself.

Sources: [6]

Pharmacovigilance and prescribing studies add context, but not evidence on persistent gastroparesis

Source 1 is a retrospective pharmacovigilance analysis of EudraVigilance reports involving tirzepatide compared with other GLP-1 receptor agonists. The reported preferred terms focused on off-label use, drug ineffectiveness, and device-related issues. This is relevant mainly because it shows the kind of events emphasized in that safety-reporting analysis. In this experiment, the abstract does not report gastric motility endpoints, gastroparesis terms, symptom duration, or long-term stomach-function outcomes, so it does not directly inform persistent gastroparesis risk.

Other provided abstracts are even less directly relevant to the question. Source 3 is a US retrospective cohort study on adherence, persistence, glycemic outcomes, weight outcomes, and pharmacy costs in people with type 2 diabetes starting tirzepatide or semaglutide. Source 4 is a prescribing-trends study in children aged 8 to 11 with obesity and no diabetes. Neither abstract reports gastric motility testing, gastroparesis diagnoses, or persistence of gastrointestinal symptoms. They can help place GLP-1 pathway drug use in a broader real-world context, but they do not answer the long-term gastric motility question.

Sources: [1][3][4]

Practical research interpretation and limitations

A careful reading of these abstracts supports a narrow conclusion: across several human study settings, gastrointestinal adverse events are repeatedly reported with GLP-1 pathway drugs or related dual agonists. In source 2, these included nausea, vomiting, and diarrhea; in source 5, gastrointestinal adverse events were the most frequent adverse event and the leading reason for discontinuation with orforglipron; in source 6, major adverse events linked with tirzepatide were gastrointestinal symptoms. These are tolerability findings, not direct measurements of gastric motility or proof of persistent gastroparesis.

The main limitation is that the abstracts do not study the outcome named in the topic. They omit formal gastric emptying endpoints, explicit gastroparesis case counts, persistence after drug withdrawal, and symptom-duration reporting. Source 1 is limited to spontaneous safety-report patterns for selected preferred terms that are not focused on gastroparesis. Source 6 is retrospective and single-arm in the abstract description. Source 2 is a concise review-style summary of clinical evidence rather than a dedicated gastric motility study. Source 5 focuses on cardiovascular safety, with gastrointestinal adverse events summarized but not characterized as persistent motility disorders.

So, if the question is whether these abstracts show long-term adverse effects on gastric motility or establish persistent gastroparesis risk, the answer is no. What they do show is that gastrointestinal adverse events are common enough to appear consistently in abstracts across trial and observational settings. What they do not show is the long-term trajectory, objective stomach-function change, or persistence required to answer the gastroparesis-risk question directly.

Sources: [2][5][6][1]